Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DDMAC Dislike: FDA Cracks Down On Facebook Widget Used On Tasigna Website

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency says Novartis' "Facebook Share" items, which users can post on their Facebook walls, must include risk along with efficacy information.

You may also be interested in...



Social Media Monitoring: The Next Frontier In Corp. Integrity Agreements?

Expert questions whether companies could be required to monitor social media posts and search engine results as part of a future corporate integrity agreement.

AstraZeneca Pulls Twitter Ads, Showing Risks Of Expansive Social Media Platforms

Company thought sponsored messages on AP’s feed were unbranded, but realized drug name showed up in expanded tweet. Did intricacies of the platform produce an inadvertent violation?

Socially Adept: Pharma Companies Must Proactively Gauge Risk Tolerance For Online Promotions, Experts Advise

Absent formal FDA guidance, pharmaceutical manufacturers must decide how much risk they are willing to take with Internet and social media product promotion and be capable of walking away from certain online venues, panelists say at the FDLI annual meeting.

Related Content

Topics

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel